Abstract: The present disclosure relates to a dental cutting zirconia blank having high relative density for preparing a dental restoration. More specifically, the present disclosure relates to a dental cutting zirconia blank which consists of a zirconia ceramics used for the cutting with the CAD/CAM system in the dental field, a semi-sinter zirconia blank (pre-sintered body) of which has high relative density, and which can provide a prosthesis device having high aesthetics after sintering.

Abstract: There is provided a method for manufacturing a group-III nitride substrate, including: (a) preparing a substrate which is made of a group III-nitride crystal and which has a high oxygen concentration domain where an oxygen concentration is higher than that of a matrix of the crystal; (b) irradiating the substrate with laser beam aiming at the high oxygen concentration domain, forming a through-hole penetrating the substrate in a thickness direction, and removing at least a part of the high oxygen concentration domain from the substrate; and (c) embedding at least a part of an inside of the through-hole by growing the group-III nitride crystal in the through-hole.

Abstract: To provide a multilayer resin material for dental milling and machining, comprising an inorganic filler in a content of 40% by weight or more and a plurality of layers different in transparency and color tone from each other, wherein the thickness of the uppermost layer (U) and the thickness of the lowermost layer (L) are each 1 mm or more, the contrast ratios (uppermost layer: CU, lowermost layer: CL) as indices for the transparency of the uppermost layer (U) and the transparency of the lowermost layer (L) satisfy the following relations: 0.30?CU?0.60 0.55?CL?0.

Abstract: To provide a multilayer resin material for dental milling and machining, comprising an inorganic filler in a content of 40% by weight or more and a plurality of layers different in transparency and color tone from each other, wherein the thickness of the uppermost layer (U) and the thickness of the lowermost layer (L) are each 1 mm or more, the contrast ratios (uppermost layer: CU, lowermost layer: CL) as indices for the transparency of the uppermost layer (U) and the transparency of the lowermost layer (L) satisfy the following relations: 0.30?CU?0.60 0.55?CL?0.

Abstract: A semiconductor substrate manufacturing method includes: epitaxially growing a columnar III nitride semiconductor single crystal on a principal place of a circular substrate; removing a hollow cylindrical region at an outer peripheral edge side of the III nitride semiconductor single crystal to leave a solid columnar region at an inside of the hollow cylindrical region of the III nitride semiconductor single crystal; and slicing the solid columnar region after removing the hollow cylindrical region. The hollow cylindrical region is removed such that the shape of the III nitride semiconductor single crystal is always keeps an axial symmetry that a center axis of the III nitride semiconductor single crystal is defined as a symmetric axis.

Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.

Abstract: The present invention relates to a dental curable composition that can be suitably used as a dental material that can substitute part or all of a natural tooth, in particular, a resin material for dental cutting and machining in the field of dental care. An object of the present invention is to provide a dental curable composition in which, when a block shape usable as a resin material for dental cutting and machining is produced while mechanical properties such as hardness, bending strength and compressive strength as well as aesthetic property required for a crown prosthetic appliance are maintained, the dental curable composition can be molded and processed with pressure and heating while strain generated in the block is reduced and no cracks and chipping occur. There is provided a dental curable composition including (a) a polymerizable monomer and (b) a filler in a weight ratio of 10:90 to 70:30, and including 0.01 to 10 parts by weight of (c) a polymerization initiator and 0.

Abstract: Provided is a silicone impression material with high hydrophilicity that exhibits instantaneous hydrophilicity before being cured, that exhibits high hydrophilicity after being cured, that has preferable properties for a dental impression material, and that has good preservation stability. A sorbitan fatty acid ester based surfactant and a nonionic surfactant composed of polyether modified silicone are used in combination as a hydrophilizing agent not containing a siloxane polymer and a hydrophilizing agent containing a siloxane polymer, respectively.

Abstract: Provided herein is a curable silicone composition that has high optical transparency after being cured and that is in a putty form to be hand-mixable. A curable silicone composition contains: a specific organopolysiloxane as a component (1); a specific organohydrogenpolysiloxane as a component (2); a filler as a component (3); and a catalyst as a component (4). The difference between the refractive index of one of the components (1) to (3) that has the highest refractive index and the refractive index of one of the components (1) to (3) that has the lowest refractive index is 0.1000 or less. The complex viscosity of any of constituent compositions of the curable silicon composition before the curable silicone composition is cured is 10 Pa·s to 100000 Pa·s, as measured under predetermined measurement condition.

Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.

Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.

Abstract: Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.

Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.

Abstract: Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.

Abstract: Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.

Abstract: An originally developed efficient signal sequence trapping method was used to screen a cDNA library prepared from cultured mast cells derived from mouse bone marrow. As a result, genes encoding type I membrane proteins and comprising a single immunoglobulin domain in the extracellular domain and a motif for transmitting an inhibitory signal into cells were successfully isolated.

Abstract: The present invention provides methods for screening compounds which inhibit activation of a member of the IL-6 signaling pathways, comprising: (a) a positive screening step using a cell capable of being killed by IL-6 stimulation to select compounds which inhibit death of the cell when it is stimulated by IL-6; and then (b) a biochemical screening step to further select compounds which inhibit activation of a member of the IL-6 signaling pathways by a biochemical means from the compounds selected in step (a). The present invention also provides compounds which inhibit activation of a member of the IL-6 signaling pathways identified using said methods.

Abstract: An originally developed efficient signal sequence trapping method was used to screen a cDNA library prepared from cultured mast cells derived from mouse bone marrow. As a result, genes encoding type I membrane proteins and comprising a single immunoglobulin domain in the extracellular domain and a motif for transmitting an inhibitory signal into cells were successfully isolated.

Abstract: A gene encoding a novel protein that is homologous to Drosophila TSG was isolated from a cDNA library derived from the AGM region of mouse embryos by using an originally developed cloning method specific to a gene encoding a membrane secretory protein. This gene is useful in developing drugs that regulate hematopoietic stem cell generation, immune and hematopoietic functions, etc.

Abstract: In a departure standby state in which a transmission is shifted to a drive stage and a mechanical clutch is disengaged, if a vehicle speed is greater than or equal to a predetermined value, the transmission is shifted to the neutral, and then the mechanical clutch is engaged. Then, it is determined whether the transmission is being rotated in reverse or not based on a rotational fluctuation on the driving side or the driven side in the process for engaging the mechanical clutch. When an accelerator pedal is pressed down at an angle greater than or equal to a predetermined angle, or when a gear shift instruction is input from the shift lever, if the transmission is being rotated in reverse the transmission is inhibited from being shifted to the drive stage, while if the transmission is not being rotated in reverse the transmission is shifted to the drive stage according to the pressed down state of the accelerator pedal, or a gear shift in instruction.